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Background/aim: Alopecia areata (AA) is an inflammatory disease with a genetic and autoimmune basis. Herein, it was aimed to study
the efficacy and safety of an immunomodulatory therapeutic agent, diphenylcyclopropenone, while manifesting its association with
histopathological features, prognostic factors, and side effects.
Materials and methods: In this retrospective study, 98 patients (60 males, 38 females) with alopecia, who were referred to the Hair
Disease Polyclinic at the Department of Dermatology, between 2011 and 2015, were included. Together with medical histories and
dermatological examinations, a skin biopsy for histopathological examination was conducted for all of the patients prior to therapy.
Therapeutic success was evaluated on the basis of the hair regrowth percentage.
Results: Regarding the overall treatment success, 33 (34%) patients had complete response, 16 (16%) had partial response (between
50% and 99%), 27 (28%) had minimal response (between 1% and 49%), and 22 (22%) were nonresponders. Both sexs were equally
represented in the outcome.
Conclusions: There was a significant relation between the severity of alopecia and the treatment outcome (P = 0.038). Patients with
AA had significantly better response when compared to those with alopecia totalis and universalis. There was no statistically significant
relation with other parameters, such as disease duration, age, sex, atopy history, age of onset, and histopathological features.
Key words: Alopecia areata, topical immunotherapy, diphenylcyclopropenone

1. Introduction
Alopecia areata (AA) is an inflammatory disease with a
genetic and autoimmune basis, leading to various degrees
of nonscarring patchy hair loss of the scalp and whole body
areas. The estimated prevalence of AA is between 0.1% and
0.2% [1]. The exact aetiology of AA is still unknown, but
genetic disposition has been identified, with some genes
like TRAF1/C5 locus. Autoimmunity also plays a major
role, with accompanying diseases of T cell auto-reactivity,
such as Hashimoto’s tiroiditis or vitiligo. According to
some studies, having a history of atopy also increases
the risk of AA [2]. Cytokines like interferon-gamma,
interleukins, and tumor necrosis factor alpha are thought
to play a major role in the pathogenesis of the disease.
Clinically, patients present with asymptomatic,
patchy hair loss, with normal appearing underlying skin.
Spontaneous resolution can occur, especially for those with
limited involvement. However many patients have a chronic
and recurrent course, with many attacks over the years.

Treatment of alopecia has always been a big challenge for
physicians. There are many different treatment modalities,
with variable efficacies, including topical, intralesional or
systemic corticosteroids, cyclosporine-A, local or systemic
phototherapy, interferon-α, photodynamic therapy,
acupuncture, topical minoxidil, anthralin, and topical
immunotherapy agents.
Topical application of diphenylcyclopropenone
(DPCP) was originally developed in 1978 by Happle et
al. [3]. The exact mechanism of action of this treatment
modality is not fully discovered. However, DPCP induces
an allergic contact dermatitis and this is thought to decrease
the T-cell-mediated immune reaction against the hair
bulb. There is also evidence that it acts on the autoreactive
T-lymphocytes within the follicular milieu to induce
apoptosis. DPCP immunotherapy has a modulatory effect
on the proinflammatory cytokines within the hair follicle,
and also provides antigenic competition, to distract the
lymphocytes from their primary target.
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In this study, the efficacy and safety of topical
immunotherapy with DPCP were evaluated retrospectively.
The favorable prognostic factors to predict the response to
DPCP immunotherapy were also assessed.
2. Material and methods
2.1. Patients and study design
In this retrospective study, 98 patients (60 males, 38
females) with alopecia areata, totalis, or universalis,
who were referred to the Hair Disease Polyclinic at the
Department of Dermatology of Cerrahpaşa Medical
Faculty, from August 2011 to June 2015, were included.
All of the patients had clinically diagnosed alopecia
and for all of them, the diagnosis was confirmed with
histopathological examination. The patients had been
resistant to any other topical or systemic conventional
therapies for at least 6 months. Prior to the therapy, the
patients were informed about the efficacy, estimated
duration, and possible side effects of the therapy, such
as enlargement of the lymph nodes on the head and
neck area; severe eczematous reactions, such as bullous
eruptions or urticarial plaques limited to the scalp or
extending to other body parts; fever, malaise and fatigue,
especially within 2 days after the treatment; and sometimes
anaphylaxis-like reactions. All of the patients gave their
informed consent. If a patient was below 18 years of age,
consent was taken from their family. The mean age of
the patients was 23.5 years, ranging from 5 to 59 years.
Exclusion criteria included current pregnancy or lactation,
being a child under the age of 5, and having vitiligo, severe
photosensitivity, or active systemic malignancies. Before
initiation of the therapy, factors such as sex, duration of
the disease, age of onset, age at the beginning of therapy,
previous treatments, history of atopy, type and severity
of hair loss (in forms of percentage), presence of ophiasis
pattern, and eyebrow, eyelash, beard, and body hair
involvement were recorded. On the first visit, a physical
assessment was performed, with emphasis on grading
the percentage of scalp involvement, type of alopecia,
and nail involvement. Prior to the therapy, a skin biopsy
of 4 mm in diameter was taken from all of the patients,
from the affected site on the scalp and histopathological
investigations were conducted. The following parameters
were assessed during the histopathological investigations
of the scalp biopsies: number of total follicular units,
number of total hair follicles, number of follicular stelae,
number of anagen, catagen and telogen hair follicles,
degree of lymphocytic infiltration of the hair follicle, and
degree of perifollicular fibrosis. The degree of fibrosis was
evaluated numerically as 0: no fibrosis, 1: mild fibrosis,
2: moderate fibrosis, and 3: severe fibrosis. Lymphocytic
infiltration was also assessed similarly, as 0: no
lymphocytic infiltration; 1: mild lymphocytic infiltration,
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which represented the involvement of less than 10% of
total number of hair follicular bulbus and the presence of
less than 3 rows of lymphocytes around each hair follicle;
2: moderate lymphocytic infiltration, which represented
involvement of 10%–50% of the hair follicular bulbus and
the presence of 3 to 6 rows of lymphocytes around each
hair follicle; and 3: severe lymphocytic infiltration, which
represented the involvement of more than 50% of all hair
follicular bulbus and the presence of more than 6 rows of
lymphocytes around each hair follicle.
At the end of the study, therapeutic success was
evaluated on the basis of the percentage of hair regrowth
on the scalp.
2.2. Treatment method with DPCP
Topical immunotherapy with DPCP was performed
following a standard protocol of sensitization. This
protocol comprised the application of a 2% concentration
of DPCP solution diluted in acetone, over an area of 2 × 2
cm on the occipital region of the scalp. The patients were
told to avoid water contact of the sensitized area for 2 days
and avoid sun exposure by using a wig or protective hat.
After 2 days, the patients were checked to detect whether
or not sensitization to DPCP had occurred. There was
a lag period of 2 weeks after the sensitization, and then
the treatment began. The initial DPCP concentration was
0.001%. DPCP solution was applied to all of the affected
areas on the scalp, together with the eyebrows, once
every week. Again after each session, the patients were
told to avoid water contact for 2 days, including excessive
sweating and sun exposure. DPCP solution was left on the
scalp for 48 h and then washed off with a mild shampoo.
The concentration of the DPCP solutions were increased
weekly, unless there were serious side effects, including
irritant contact dermatitis and photoallergic reactions,
and the final concentration of 2% was reached at the end
of week 6. Concentrations of 0.001%, 0.01%, 0.1%, 0.2%,
0.5%, 1%, and 2% were applied sequentially.
2.3. Follow-up and assessment of efficacy
During follow-up visits, the side effects of the patients
were recorded, as well as the grade of hair regrowth.
Once complete or cosmetically acceptable hair regrowth
(amount of growth that eliminated the need for using
a wig or hat) was achieved, the intervals of the DPCP
application were prolonged to 2 weeks, 3 weeks, and
monthly. By this method, the DPCP immunotherapy was
discontinued gradually. In the case of hair loss during
this tapering-off period, therapy was restored at weekly
intervals. If there was no obvious response at the end of
6 months, immunotherapy was considered as noneffective
and discontinued.
2.4. Statistical analysis
Statistical analyses were performed using SPSS 19.0 for
Windows (SPSS Inc., Armonk, NY). The Mann–Whitney,
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Wilcoxon, and Kruskal-Wallis statistical tests were
performed for each data set and P < 0.05 was considered
as statistically significant.
3. Results
The mean age of the patients was 23.2 years, ranging from
5 to 59 years. The mean age of the male patients was 21.8
years, with a standard deviation of 12.4. The mean age
of the female patients was 25.5 years, with a standard
deviation of 15.6. The demographic and clinical data are
shown in Table 1. The mean period of disease was 4.2 years
before the DPCP treatment (Table 1).
Among the 98 patients, 49 (50%) were diagnosed
with AA, while 19 (19.4%) had alopecia totalis, and 30
(30.6%) had alopecia universalis. At the beginning of the
immunotherapy, 9 (9.25%) of the patients had less than
25% hair loss, which according to the Alopecia Areata
Investigational Assessment Guidelines, was categorized as
S1, while 13 (13.25%) had between 25% and 50% (S2), 16
(16.25%) had between 50% and 75% (S3), and 11 (11.25%)
had between 75% and 99% (S4). Of the patients, 49 (50%)
had total hair loss on the scalp area (S5), with a diagnosis
of alopecia totalis or universalis.
Additionally, 20 (20.4%) patients had a previous history
of atopy, including atopic dermatitis or allergic asthma.
With regards to the previous treatments, 37 (37.7%)
patients had used only topical treatment modalities,
including topical corticosteroids, minoxidil (2% or
5% concentration), and intralesional corticosteroid
injections. Of the patients, 61 (62.3%) had tried both
topical and systemic treatment options, including systemic
corticosteroids, cyclosporine, and ultraviolet therapy.

The mean duration of DPCP immunotherapy in the
analyzed cohort was 13.1 months, with a minimum of 4
months and a maximum of 44 months.
Regarding the overall treatment success, 33 (34%)
patients had complete response (Figure 1A shows the
pretreatment phase and Figure 1B shows complete response
at 4 months posttreatment), 16 (16%) patients had partial
response (between 50% and 99%) (Figure 2A shows the
pretreatment phase and Figure 2B shows a cosmetically
acceptable response at 7 months of treatment), 27 (28%)
patients had minimal response (between 1% and 49%),
and 22 (22%) patients were nonresponders (Figure 3A
shows the pretreatment phase and Figure 3B shows the
skin of the patient who did not respond to 6 months of
treatment). Both sexes were equally represented in the
outcome.
Among the 22 nonresponding patients, 8 responded
by 100% and 7 responded by 75%–99% during the course
of the therapy followed by a sudden and complete loss of
hair.
The Mann–Whitney U test was used to investigate the
relation between the type of alopecia and the treatment
result. Statistical analyses revealed a significant relation
between the type and severity of alopecia and the treatment
outcome (P = 0.038). AA patients had significantly better
response to the treatment when compared to the alopecia
totalis or alopecia universalis patients. On the other hand,
there was no statistically significant difference between
the success rate of the therapy and the other parameters,
such as the disease duration before DPCP therapy, age, sex,
atopy history, age of onset of alopecia, and age at start of
DPCP immunotherapy.

Table 1. Demographic and clinical data.
Demographic data
Number of patients

98

Sex (M/F)

M: 60 (61%)/F: 38 (39%)

Mean age

23.2 years (Male: 21.8, Female: 25.5)

Age at onset

Mean: 28 years, Range: 4–55 years

Disease duration

4.2 years

Previous local treatments

37 patients

Previous systemic treatments

61 patients

Mean treatment duration (months)

13.1

Mean treatment sessions

50.5

Clinical data
Type of alopecia
Alopecia areata

49

Alopecia totalis

19

Alopecia universalis

30
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Figure 1. (A) Appearance of the patient before DPCP. (B) Full clinical response after 4 months of DPCP treatment.

Figure 2. (A) Appearance of the patient before DPCP. (B) Cosmetically acceptable response after 7 months of DPCP treatment.

Histopathological parameters were also compared
with the success rates of the treatment, but there were
no significant relationships with regards to the presence
of fibrosis, lymphocytic infiltration, number of follicular
stelae, and number of catagen hair follicles (Table 2; P =
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0.478, P = 0.148, P = 0.994, and P = 0.118, respectively)
Figure 4A shows mild fibrosis, Figure 4B shows moderate
fibrosis, and Figure 4C shows severe fibrosis. In the case of
lymphocyte infiltration, Figure 4D shows mild lymphocyte
infiltration, Figure 4E shows moderate lymphocyte

KUTLUBAY et al. / Turk J Med Sci

Figure 3. (A) Appearance of the patient before DPCP. (B) Patient not responding 6 months of DPCP treatment.
Table 2. Success rates and histopathological parameters with a comparison to the type of alopecia.
Type of Alopecia

Average success
rate

P-value

Average lymphocytic
infiltration*

Average fibrosis**

Alopecia areata (0%–25%)

74 %

0,012

2.7

1.4

Alopecia areata (25%–50%)

70 %

0.022

1.5

2.4

Alopecia areata (50%–75%)

67 %

0.034

1.6

1.9

Alopecia areata (75%–99%)

60 %

0.040

1.9

2.1

Alopecia totalis

55 %

0.045

2.1

2.0

Alopecia universalis

53 %

0.039

1.2

2.1

* Lymphocytic infiltration is valued as 0: no lymphocytic infiltration, 1: mild. lymphocytic infiltration 2: moderate
lymphocytic infiltration 3: severe lymphocytic infiltration
**Fibrosis is valued as 0: no fibrosis, 1: mild fibrosis 2: moderate fibrosis 3: severe fibrosis

infiltration, and Figure 4F shows intense lymphocyte
infiltration.
The total number of sessions and thus, duration
of therapy, that the patients received were found to be
positively and significantly correlated with the success
rates, meaning that the more sessions a patient received
and the longer the therapy continued, and the better their
response was.
During the sensitization process, almost all of the
patients experienced minimal erythema, itching, and
burning sensation over the affected area. However, during
the course of the therapy, among the 98 patients, 56 (57%)
showed no side effects and 38 (38%) complained about

minimal erythema and sensitivity over the scalp, especially
during the subsequent 2 days after the application. Other
common side effects included pruritus, dermatitis, vesicles,
bullae, and flu-like symptoms. Of the patients, 4 (4%) had
serious side effects, such as lymph node enlargement,
fever, and general malaise; 3 (3%) had irreversible
hyperpigmentation of the head and neck area, and 2 (2%)
developed vitiligo macules.
4. Discussion
AA is an organ-specific autoimmune disease, and the
stem cells of the hair follicles are characteristically spared,
which implies a potential for regrowth of the hair. Despite
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Figure 4. (A) Mild fibrosis, HEX400. (B) Moderate degree of fibrosis, HEX400. (C) Severe fibrosis, HEX400. (D) Mild degree of
lymphocyte infiltration, HEX400. (E) Moderate degree of lymphocyte infiltration, HEX400. (F) Intense lymphocyte infiltration,
HEX400.

this fact, to date, there remains no curative treatment for
AA and none of the existing treatment options have been
able to alter the course of the disease. Phototherapy or
photochemotherapy, topical and oral corticosteroids, and
cyclosporine and biological agents, such as efalizumab
and etanercept, have all been used with various success
rates [4–8]. Among these treatment options, topical
immunotherapy agents have revealed promising clinical
success with low side effect profiles. Topical sensitizers,
such as dinitrochlorobenzene, SADBE, or DPCP create
an allergic contact dermatitis, via delayed-type (type IV)
hypersensitivity reaction [9]. Dinitrochlorobenzene is a
highly mutagenic and squaric acid dibutylester that can
easily lose stability in the case of long-term use and high
temperatures [10]. Thus, DPCP was the choice of topical
agents for this study, as well as many others in the literature
[11]. The exact mechanism of action for DPCP has still not
been clarified; however, the likelihood of a regulatory-T
lymphocyte mediated role within the follicular unit is
high [12]. Although antigenic competition with the
responsible antigens has been by far the most accepted
theory, other remarkable effects over the cytokine system
have included increased IL-10 secretion and low CD4+ to
CD8+ T cell ratios, together with the induction of other
immunomodulatory substances, such as CTLA4 [13,14].
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In many studies of DPCP topical immunotherapy,
initially, the solution was applied to one half of the scalp
and only after there was hair growth, was the treatment
extended to the entire scalp [15]. This approach aimed to
determine the efficiency of the treatment while minimizing
the side effects. However in the current study, after the
sensitization process, the solution was applied to all of
the hairless areas of the scalp, so as to obtain cosmetically
acceptable results sooner.
In many studies, it was reported that combination
therapy with minoxidil or other agents did not improve the
success rates [16–18]. Therefore, any topical or systemic
treatment other than DPCP was not given to the patient
group.
The studies have revealed a wide range of treatment
efficacies, with a success rate of up to 85% for cosmetically
acceptable hair regrowth. In a study of 148 patients, 100%
regrowth rate was achieved for patients with less than
50% hair loss [19–24]. This wide range of results could
have been due to differences in the treatment protocols,
data sets, evaluation methodology, prognostic factors,
absence of uniform terminology for evaluating the results,
and differences between the statistical methods used for
analyzing the results. Some studies, on the other hand, have
shown no differences between topical immunotherapy
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and placebo or other treatment modalities, such as
topical corticosteroids, especially for patients with limited
alopecia lesions [25,26]. These findings contradicted the
previous data in the literature, as well as the current study,
which clearly showed a better response in cases with
limited involvement. According to the overall results of the
studies in the literature, DPCP immunotherapy for AA is a
powerful option with a limited side effect profile.
According to the previous efficacy studies of DPCP,
chronic and extensive disease, and accompanying nail
changes were reported to be poor prognostic factors [20],
while limited involvement for a short period of time,
absence of nail changes, older age of onset, and a negative
history of atopic dermatitis correlated with a more
favorable prognosis [27,28].
In the case series herein, the success rate and treatment
response were only associated with the extent of hair
loss and thus, the type of alopecia. Patients with limited
AA had better prognosis and good response to therapy,
while extensively involved alopecia totalis and alopecia
universalis cases had worse a prognosis and resistant
course. Other parameters, such as sex, duration of the
disease, atopy history, age of onset of alopecia, and age at
start of DPCP immunotherapy had basically no effect on
the prognosis of the disease during DPCP immunotherapy.
Many other studies have also supported this finding, with
the severity of alopecia being the sole important factor for
the outcome of the treatment [21,22].
Many adverse events have been reported due to the use
of DPCP, including eczematous reactions, urticaria, vitiligo,
lymphadenopathy, hyperpigmentation, or erythema
multiforme-like reactions [18]. In the current study,

during the sensitization process, almost all of the patients
experienced minimal erythema, itching, and burning
sensation. Overall, the most commonly encountered side
effect was erythema and itching, followed by the formation
of papules, vesicles, bullae, and flu-like symptoms. Other
less frequent side effects were lymph node enlargement,
fever, general malaise, irreversible hyperpigmentation of
the head and neck area, and vitiligo macules.
The use of DPCP in children is still a controversial
area, although some studies have shown good results with
acceptable side effect profiles [29]. In the current study,
children above 5 years of age were also included and the
treatment results or safety parameters were similar to
those of the adult patients.
AA can have serious aesthetic and psychological
consequences for patients due to its unpredictable course,
consisting of spontaneous remissions and relapses. All of
the conventional treatment options have a limited chance
of success. Topical DPCP immunotherapy is a safe and
effective alternative for patients with resistant disease and
long-term results will provide more precise data about the
success rate of this treatment modality.
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